Here's Why CNX Resources Corporation (CNX) Traded Lower in Q1
Longleaf Partners, managed by Southeastern Asset Management, released its 'Partners Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -5.14% in the first quarter, compared to the S&P 500's -4.27% return and Russell 1000 Value's 2.14% return. The firm's stock price performance was volatile, but its confidence in future returns grew as the quarter progressed. The firm invested in quality companies that it thinks are strong and resilient to difficult circumstances. The portfolio has significantly outperformed the index, demonstrating this resiliency since the market peak on February 19th. The rise of its underlying value per share outpaced the performance of the stock price during the quarter. For more information on the fund's best picks in 2025, please check its top five holdings.
In its first-quarter 2025 investor letter, Longleaf Partners Fund highlighted stocks such as CNX Resources Corporation (NYSE:CNX). CNX Resources Corporation (NYSE:CNX) is an independent natural gas and midstream company. The one-month return of CNX Resources Corporation (NYSE:CNX) was -3.78%, and its shares gained 30.04% of their value over the last 52 weeks. On April 17, 2025, CNX Resources Corporation (NYSE:CNX) stock closed at $30.82 per share with a market capitalization of $4.537 billion.
Longleaf Partners Fund stated the following regarding CNX Resources Corporation (NYSE:CNX) in its Q1 2025 investor letter:
"CNX Resources – Natural gas company CNX Resources was a detractor for the quarter. While CNX Resources Corporation (NYSE:CNX) was one of our stronger performers in 2024, it started the year with a disappointing outcome regarding government incentives for its coal mine methane gas capture program. The incentives were below our unrisked upside case that could have helped our value by $10-20/share+. While this was a disappointing few dollars per share hit to our risked value, the silver lining is that both we and CNX were able to buy more shares at a price that, in our view, does not fully appreciate all the other good things going on at the company. CNX remains focused on what is within its control, leveraging its low-cost structure and disciplined hedging strategy to generate FCF in a variety of price environments."
A long line of heavy-duty trucks transporting natural gas across a rural highway.
CNX Resources Corporation (NYSE:CNX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held CNX Resources Corporation (NYSE:CNX) at the end of the fourth quarter which was 31 in the previous quarter. While we acknowledge the potential of CNX Resources Corporation (NYSE:CNX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we covered CNX Resources Corporation (NYSE:CNX) and shared the list of billionaire's favorite oil and gas stocks. CNX Resources Corporation (NYSE:CNX) was one of the strongest performers of Longleaf Partners Fund in 2024 and Q4 2024. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
27 minutes ago
- CNBC
Stock futures are near flat as U.S.-China trade talks continue, May inflation report looms: Live updates
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., March 19, 2025. Brendan Mcdermid | Reuters Stock futures were little changed on Tuesday evening as investors awaited progress on trade policy talks between the U.S. and China. They also anticipated the release of May's consumer inflation report. Futures tied to the S&P 500 slipped 0.07%, while Nasdaq 100 futures pulled back 0.05%. Dow Jones Industrial Average futures lost 28 points, or 0.07%. Trade talks between U.S. and Beijing officials continued for a second day in London on Tuesday. U.S. Treasury Secretary Scott Bessent said he would be departing the ongoing trade talks with China, but U.S. Commerce Secretary Howard Lutnick and U.S. Trade Representative Jamieson Greer would remain to continue the negotiations. Discussions could extend into Wednesday if needed, Lutnick said earlier. The discussions are a key focus for investors and a broader market that remains jittery toward any jolts on trade policy. Both China and the U.S. previously agreed to temporarily pause high tariffs on one another in May, although a fully ironed out agreement has yet to materialize. In regular trading on Tuesday, the S&P 500 rose about 0.6%, posting a third straight positive session. The broad market index sits less than 2% off the high it notched in February. The Nasdaq Composite added 0.6% on Tuesday, while the 30-stock Dow climbed 0.3%. Even as stocks have been resurging, tariff fears and rising bond yields could hang over the market, according to Deutsche Bank. "One key concern is that the Trump administration, buoyed by the market rebound, may resume aggressive tariff rhetoric—potentially triggering renewed retaliation from China and Europe, as seen earlier this year," the firm's group chief economist David Folkerts-Landau said in a Tuesday note. "At the same time, rising long-end bond yields are amplifying fiscal concerns globally, particularly given plans for expanded deficits across multiple major economies," he added. "With several countries already on unsustainable debt paths, the events of 2025 may have accelerated an inevitable reckoning." Investors will get further insight into the U.S. economy on Wednesday morning as the Bureau of Labor Statistics rolls out May's reading of the consumer price index. Economists polled by Dow Jones call for a 0.2% month-over-month increase, while headline CPI is anticipated to have grown 2.4% from 12 months earlier. A hot report could spook investors who are already on edge over inflationary pressures. "Ultimately this report is not expected to cause any significant changes to the Fed's current wait and see approach when it comes to setting rates," said Sam Millette, director of fixed income at Commonwealth Financial Network. "With that being said, we'll have to wait and see if the report shows the anticipated modest rise in price pressure that's expected or if there are any surprises in store for investors." On the earnings front Wednesday, traders will look for reports from Chewy and Oracle .
Yahoo
32 minutes ago
- Yahoo
Byline Bancorp, Inc. Announces Commencement of Secondary Public Offering of Common Stock and Concurrent Share Repurchase
CHICAGO, June 10, 2025--(BUSINESS WIRE)--Byline Bancorp, Inc. ("Byline" or the "Company") (NYSE: BY) announced today that the Estate of Daniel L. Goodwin (the "Estate") and Equity Shares Investors, LLC, an affiliate of the Estate, the selling stockholders of the Company (the "Selling Stockholders"), are offering for sale to the public a total of 4,282,210 shares (the "Offered Shares") of the Company's common stock (the "Secondary Offering"). The Company is not offering or selling any shares of its common stock in the Secondary Offering and will not receive any proceeds from the sale of its shares of common stock in the Secondary Offering. In addition, the Company intends to purchase from the underwriter between $5 million and $10 million of the shares of common stock in the Secondary Offering (the "Share Repurchase"), at a price per share equal to the price per share to be paid by the underwriter to the Selling Stockholders. The Company intends to execute the Share Repurchase as part of its existing share repurchase program authorized on January 1, 2025. The underwriter will not receive any discount or commission in respect of the shares of common stock being purchased by the Company in the Share Repurchase. The Share Repurchase is conditioned upon the completion of the Secondary Offering, as well as the satisfaction of customary closing conditions, and is expected to close concurrently with the completion of the Secondary Offering. Certain of the Company's directors have indicated an interest in purchasing up to an aggregate $3.1 million in shares of common stock in the Secondary Offering at the public offering price and on the same terms as the other purchasers in the Secondary Offering. J.P. Morgan is serving as the sole underwriter for the Secondary Offering. An automatically effective shelf registration statement on Form S-3 relating to the shares of the Company's common stock subject to the Secondary Offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and is available on the SEC's website at The Secondary Offering will be made only by means of a prospectus supplement and accompanying prospectus that forms a part of the registration statement, copies of which may be obtained, when available, by request from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@ and postsalemanualrequests@ This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. About Byline Bancorp, Inc. Headquartered in Chicago, Byline Bancorp, Inc. is the parent company of Byline Bank, a full service commercial bank serving small- and medium-sized businesses, financial sponsors, and consumers. Byline Bank has approximately $9.6 billion in assets and operates 46 branch locations throughout the Chicago and Milwaukee metropolitan areas. Byline Bank offers a broad range of commercial and community banking products and services including small ticket equipment leasing solutions and is one of the top Small Business Administration lenders in the United States. Forward-Looking Statements This press release may contain "forward-looking statements" including statements concerning the size and terms of the Secondary Offering and the size and terms of the Share Repurchase. All statements other than statements of historical facts contained in this press release may be forward-looking statements. In some cases, you can identify the forward-looking statements by the use of words such as "may," "could," "should," "would," "expect," "plan," "anticipate," "intend," "forecast," "believe," "estimate," "predict," "propose," "potential," "continue," "scheduled," or the negative of these terms or other comparable terminology. These forward-looking statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to those set forth in the periodic reports Byline files with the SEC and those described in the registration statement and the prospectus supplement and accompanying prospectus related to the Secondary Offering. All forward-looking statements included in this press release are made only as of the date of this press release. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, we cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. We expressly disclaim any obligation to update or revise any forward-looking statements, whether because of future events, new information, a change in our views or expectations, or otherwise. We make no prediction or statement about the performance of our common stock. View source version on Contacts Contact For Byline Bancorp, Inc.: Investors / Media: Brooks O. RennieHead of Investor RelationsByline Bank(312) 660-5805brennie@
Yahoo
36 minutes ago
- Yahoo
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ("Philochem'), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. ('RayzeBio'), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated with the OncoACP3 diagnostic has been promising, displaying selective tumour uptake and long residence time with minimal healthy tissue uptake. IND-enabling activities to support the application for a Phase I therapeutic study with 225Ac-OncoACP3 are ongoing. Prof. Dr. Dario Neri, CEO and CSO of Philogen, commented: 'We are delighted to enter into this new collaboration with RayzeBio, a leader in the field of radiopharmaceutical medicines. This partnership will focus on the development and commercialization of OncoACP3 for both diagnostic and therapeutic applications in prostate cancer. OncoACP3 is a best-in-class targeting agent with the potential to become a breakthrough treatment in this field. This collaboration reflects our shared commitment to translating scientific innovation into meaningful clinical solutions, making OncoACP3 therapies widely available to patients in need.' Ben Hickey, President, RayzeBio commented: 'This collaboration with Philochem enhances our leadership in the rapidly advancing radiopharmaceuticals space, consistent with our strategy to bring forward best-in-class RPT candidates. OncoACP3, with its initial encouraging safety profile, provides a differentiated entry for Bristol Myers Squibb and RayzeBio into the prostate cancer arena, building on our leadership in actinium-based RPT development. This agreement is a significant milestone for RayzeBio and our goal to deliver radiopharmaceuticals to patients.' Under the terms of the agreement, Philochem will receive an up-front payment of $350m and up to $1.0bn in development, regulatory and commercial milestones. The company will also receive mid-single to low double-digit royalties payable on Global Net Sales of both Therapeutic and Diagnostic agents of OncoACP3. The closing of the transaction is subject to regulatory approvals and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2025. For Philochem, Centerview Partners UK LLP is acting as exclusive financial advisor and Cooley LLP is acting as exclusive legal counsel. About Philogen group Philogen is an Italian-Swiss group active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Philogen's mission is to discover, develop and market innovative pharmaceuticals for the treatment of diseases of high unmet need. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. FOR MORE INFORMATION Philogen - Investor Relations IR@ - Emanuele Puca | Investor RelationsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
